{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T14:27:53Z","timestamp":1754144873866,"version":"3.41.2"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Hepatoid adenocarcinoma (HAC) is a specific extrahepatic adenocarcinoma with hepatocellular differentiation, often associated with elevated serum alpha-fetoprotein (AFP). HAC has been reported to occur in the stomach, ovaries, pancreas, uterus, and other sites. Despite the poor prognosis and few effective treatment options, timely and accurate histopathological diagnosis is essential to optimize clinical management for long-term survival. HAC of the uterine cervix is very rare and occurs mainly in postmenopausal women, and the first symptom is irregular vaginal bleeding in all cases, with elevated serum AFP values. HAC of the cervix is more prone to metastasis than ordinary cervical adenocarcinoma, and its prognosis is worse. The treatment plan still refers to the surgical treatment plan for cervical cancer, and radiotherapy or platinum-based combination chemotherapy is given after surgery. With the development of molecular pathology and next-generation sequencing technology, the pathogenesis of HAC is mainly related to hepatoid differentiation, gene mutation, and inflammatory stimulation. Only two cases have been reported in the literature, and one of the reasons for the lack of reports is the lack of knowledge of the clinical and pathological features of the disease; thus, improving the clinical understanding of HAC is crucial for better identifying patients with HAC of the cervix.<\/jats:p>","DOI":"10.3389\/fonc.2025.1551657","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T04:13:27Z","timestamp":1752639207000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinicopathological features and pathogenesis of hepatoid adenocarcinoma of the uterine cervix: a case report"],"prefix":"10.3389","volume":"15","author":[{"given":"Yuanyuan","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renfeng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"633916","DOI":"10.3389\/fonc.2021.633916","article-title":"Hepatoid Adenocarcinoma of the Stomach: Current Perspectives and New Developments[J","author":"Xia","year":"2021","journal-title":"Front Oncol"},{"key":"B2","article-title":"An AFP-producing gastric carcinoma with features of hepatic differentiation","volume":"56","author":"Ishikura","year":"1985","journal-title":"A Case report Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1438.2007.00901.x","article-title":"Primary hepatoid adenocarcinoma of the uterine cervix[J","volume":"17","author":"Kato","year":"2007","journal-title":".Int J Gynecol Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.16150\/j.1671-2870.2019.06.015","article-title":"Hepatoid adenocarcinoma of the uterine cervix: A case report and literature review [J","volume":"18","author":"Liu","year":"2019","journal-title":"J Diagnostics Concepts Practices"},{"key":"B5","doi-asserted-by":"publisher","first-page":"216104","DOI":"10.1016\/j.canlet.2023.216104","article-title":"Hepatoid adenocarcinoma\u2014Clinicopathological features and molecular characteristics[J","volume":"559","author":"Li","year":"2023","journal-title":"Cancer Lett"},{"key":"B6","doi-asserted-by":"crossref","DOI":"10.1177\/2632010X221088961","article-title":"Hepatoid adenocarcinoma of the lung: a rare form of lung cancer","volume":"15","author":"Laraqui Houssein","year":"2022","journal-title":"Clin Pathol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19940401)73:7<1919::AID-CNCR2820730724>3.0.CO;2-L","article-title":"Hepatoid adenocarcinoma in the urinary bladder. Unusual localization of a newly recognized tumor type[J","volume":"73","author":"Sinard","year":"1994","journal-title":". Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"3849","DOI":"10.3390\/cancers14163849","article-title":"Comprehensive analysis of genomic alterations in hepatoid adenocarcinoma of the stomach and identification of clinically actionable alterations[J","volume":"14","author":"Zhao","year":"2022","journal-title":"Cancers"},{"key":"B9","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/s41419-020-03030-7","article-title":"AFP promotes HCC progression bysuppressing the HuR-mediated Fas\/FADD apoptotic pathway[J","volume":"11","author":"Chen","year":"2020","journal-title":"Cell Death Dis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-019-00965-5","article-title":"Hepatoid adenocarcinoma of the stomach: a unique subgroup with distinct clinicopathological and molecular features[J","volume":"22","author":"Wang","year":"2019","journal-title":"Gastric Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"702216","DOI":"10.3389\/fonc.2021.702216","article-title":"Hepatoid adenocarcinoma of the lung: a systematic review of the literature from 1981 to 2020[J","volume":"6","author":"Hou","year":"2021","journal-title":"Front Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.v42.10","article-title":"Genomic Profiling and the Impact of MUC19 Mutation in Hepatoid Adenocarcinoma of the Stomach[J","volume":"42","author":"Zhu","year":"2022","journal-title":"Cancer Commun (Lond)"},{"key":"B13","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.humpath.2021.09.006","article-title":"Genomic characterization of hepatoidtumors: context matters[J","volume":"118","author":"Lawlor","year":"2021","journal-title":"Hum Pathol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S276969","article-title":"Effect of immune checkpoint inhibitors plus chemotherapy on advanced gastric cancer patients with elevated serum AFP or hepatoid adenocarcinoma[J","volume":"2","author":"Li","year":"2020","journal-title":"Cancer Manag Res"},{"key":"B15","article-title":"Relationship between PD-L1 expression in and clinicopathological features of hepatoid adenocarcinoma of stomach and its impact on prognosis","volume":"35","author":"Tao","year":"2022","journal-title":"Cancer Control Treat"},{"key":"B16","doi-asserted-by":"publisher","first-page":"3000605221091095","DOI":"10.1177\/03000605221091095","article-title":"Effect of immune checkpoint inhibitors in patients with gastric hepatoid adenocarcinoma:a case report and literature review[J","volume":"50","author":"Sun","year":"2022","journal-title":"J Int Med Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.v106:4","article-title":"Histogenesis of hepatoid adenocarcinoma of the stomach: molecular evidence of identical origin with coexistent tubular adenocarcinoma[J","volume":"106","author":"Akiyama","year":"2003","journal-title":"Int J Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2020-4747","article-title":"Abstract 4747: genomic and transcriptomic landscape of AFP-producing gastrointestinal adenocarcinoma","author":"Li","year":"2020","journal-title":"Proceedings: AACR Annu Meeting"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0619","article-title":"Genetic alterations of the ATBF1 gene in gastric cancer[J","volume":"13","author":"Cho","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B20","article-title":"Abstract 4746: genomic alterations and clinical correlations of Chinese hepatoid adenocarcinoma patients","author":"Liu","year":"2020","journal-title":"Proceedings: AACR Annu Meeting 2020"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.17305\/bb.2024.10445","article-title":"Development of dynamic nomogram for predicting cancer-specific survival in hepatoid adenocarcinoma: A comprehensive SEER-based population analysis","volume":"24","author":"Wang","year":"2024","journal-title":"Biomol Biomed"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2017.3982","article-title":"Antibody to human \u03b1-fetoprotein inhibits cell growth of human hepatocellular carcinoma cells by resuscitating the PTEN molecule: in vitro experiments","volume":"50","author":"Ohkawa","year":"2017","journal-title":"Int J Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1186\/s12885-015-1384-9","article-title":"HBx induced AFP receptor expressed to activate PI3K\/AKT signal to promote expression of Src in liver cells and hepatoma cells[J","volume":"6","author":"Zhu","year":"2015","journal-title":"BMC Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S97941","article-title":"JAK2 inhibitor combined with DC-activated AFP-specific T-cells enhances antitumor function in a Fas\/FasL signal-independent pathway[J","volume":"20","author":"Liu","year":"2016","journal-title":"OncoTargets Ther"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.2016.20.issue-3","article-title":"Alpha fetoprotein plays a critical role in promoting metastasis of hepatocellular carcinoma cells[J","volume":"20","author":"Lu","year":"2016","journal-title":"J Cell Mol Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i41.4643","article-title":"Role of autophagy in tumorigenesis, metastasis,targeted therapy and drug resistance of hepatocellular carcinoma[J","volume":"24","author":"Huang","year":"2018","journal-title":"World J Gastroenterol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.2001.6383","article-title":"An alpha-fetoprotein-producing hepatoid adenocarcinoma of the endometrium","volume":"83","author":"Adams","year":"2001","journal-title":"Gynecol Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1551657\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T04:13:29Z","timestamp":1752639209000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1551657\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,16]]},"references-count":27,"alternative-id":["10.3389\/fonc.2025.1551657"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1551657","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2025,7,16]]},"article-number":"1551657"}}